🔗 Share this article

Given that the US continues making unprecedented revisions to its vaccine recommendations, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations in the global health crisis and has concentrated on potential deaths after Covid immunization in her recent time at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Schedule

Health officials were set to unveil major changes to the childhood vaccine schedule in December, synchronizing the US with the Danish vaccine program, sources say – a significant shift that would put the US at odds with a large portion of the global community with no evidence for improved outcomes. The planned update has been postponed until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to present at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to run the division this year.

A New Direction at the FDA

This interim role might represent a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Høeg has frequently advocated for ending certain childhood vaccine recommendations in the US in order to be more similar to the Danish model, a country with universal health coverage and a citizenry roughly the population of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – typically the responsibility of Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Expertise

Høeg has no apparent background in medication creation, approval processes or management, which has been customary for past directors of the biologics center. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for running the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in managing a sizeable institution. She is not an expert in industry regulation.”

Previous commissioners of CBER would “understand laws and regulations and the science of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she doesn’t have the type of experience that previous people who headed CBER have had.”

CDER has an immense range of responsibilities at the agency, Woodcock stated.

“Many people just pays attention on the innovative therapies, but the off-patent medication office approves a multitude of generic medications. There’s a biosimilars program, non-prescription drug unit and so forth, and all of those must be supervised,” Woodcock noted. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major management element to the job, which oversees in excess of 5,000 staff members. “It’s a huge administrative position, if you do it right,” she concluded.

Response and Contentious Policies

In response to questions about Høeg’s qualifications and whether this assignment indicates increased cooperation among agency officials on vaccines, a press secretary responded that the “inquiries stem from flawed assumptions”.

“Her resume matches the responsibilities of her role,” the official stated, citing the months Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s controversial priority voucher program, a controversial one-day therapy clearance system that apparently concerned her preceding directors. “By what process are these medications being picked for this expedited pathway? Who takes the choices?” Howard asked. “There is a lot of confidentiality occurring at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards laxer oversight of all drugs, aside from vaccines.”

Established Past Work on Immunizations

Concerning vaccines, Høeg has a more documented, if troubling, track record, some experts have noted. She released a analysis using unverified public submissions to determine the incidence of myocarditis after Covid vaccination. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to imply Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership encompassed altering rules for recently developed shots and discontinuing “optional” vaccines, she remarked after the election on a podcast. At the FDA, Dr. Høeg has according to sources suggested excluding young men from getting Covid vaccinations.

“She is an thorough dogmatist who starts off with her conclusions and reverse-engineers to accommodate the data in a highly misleading, fraudulent fashion,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with fellow contrarians, {like|